Compare Stocks: ACET, ADMA, SABS, and IMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.88 -1.4%	$8.60	$6.01 ▼ $17.44	$83.12M	1.6	126,033 shs	54,878 shs
ADMA ADMA Biologics	$9.43 -0.5%	$9.05	$7.21 ▼ $20.46	$2.11B	0.74	4.40 million shs	505,081 shs
IMRX Immuneering	$5.02 -3.6%	$4.81	$3.86 ▼ $10.08	$324.78M	0.43	1.36 million shs	448,806 shs
SABS SAB Biotherapeutics	$3.84 -2.3%	$3.75	$1.85 ▼ $5.15	$349.39M	0.53	648,971 shs	106,899 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+0.67%	-3.94%	+9.88%	-3.22%	-25.47%
ADMA ADMA Biologics	-1.56%	-2.87%	+7.85%	+18.80%	-45.04%
IMRX Immuneering	+1.17%	-0.76%	+22.88%	-9.71%	+0.39%
SABS SAB Biotherapeutics	+1.29%	+6.22%	+13.91%	+9.17%	+85.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$8.88 -1.4%	$8.60	$6.01 ▼ $17.44	$83.12M	1.6	126,033 shs	54,878 shs
ADMA ADMA Biologics	$9.43 -0.5%	$9.05	$7.21 ▼ $20.46	$2.11B	0.74	4.40 million shs	505,081 shs
IMRX Immuneering	$5.02 -3.6%	$4.81	$3.86 ▼ $10.08	$324.78M	0.43	1.36 million shs	448,806 shs
SABS SAB Biotherapeutics	$3.84 -2.3%	$3.75	$1.85 ▼ $5.15	$349.39M	0.53	648,971 shs	106,899 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+0.67%	-3.94%	+9.88%	-3.22%	-25.47%
ADMA ADMA Biologics	-1.56%	-2.87%	+7.85%	+18.80%	-45.04%
IMRX Immuneering	+1.17%	-0.76%	+22.88%	-9.71%	+0.39%
SABS SAB Biotherapeutics	+1.29%	+6.22%	+13.91%	+9.17%	+85.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.75	Moderate Buy	$46.80	427.03% Upside
ADMA ADMA Biologics	2.33	Hold	$18.67	97.95% Upside
IMRX Immuneering	3.00	Buy	$17.50	248.61% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	212.50% Upside

Current Analyst Ratings Breakdown

Latest ACET, ADMA, SABS, and IMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	IMRX Immuneering	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	ACET Adicet Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (E+)
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
8/6/2026	IMRX Immuneering	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/6/2026	IMRX Immuneering	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$14.00
8/4/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/3/2026	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/20/2026	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $18.00
7/15/2026	ADMA ADMA Biologics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $17.00

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$12.83 per share	N/A
ADMA ADMA Biologics	$510.17M	4.14	$0.64 per share	14.72	$1.82 per share	5.18
IMRX Immuneering	N/A	N/A	N/A	N/A	$2.95 per share	N/A
SABS SAB Biotherapeutics	N/A	N/A	$0.34 per share	11.35	$2.36 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	11/11/2026 (Estimated)
ADMA ADMA Biologics	$146.93M	$0.70	13.47	11.09	N/A	32.98%	40.17%	26.97%	11/4/2026 (Estimated)
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	11/11/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest ACET, ADMA, SABS, and IMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	6.71
ADMA ADMA Biologics	0.49	6.97	3.81
IMRX Immuneering	N/A	19.47	19.47
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
ADMA ADMA Biologics	75.68%
IMRX Immuneering	67.65%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
ADMA ADMA Biologics	3.90%
IMRX Immuneering	14.90%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	90	9.36 million	9.04 million	Optionable
ADMA ADMA Biologics	530	223.99 million	215.25 million	Optionable
IMRX Immuneering	60	64.70 million	55.06 million	Not Optionable
SABS SAB Biotherapeutics	140	90.99 million	84.26 million	Not Optionable

ACET, ADMA, SABS, and IMRX Headlines

Recent News About These Companies

375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.

August 26 at 3:22 AM | marketbeat.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst

August 10, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SABS Q3 Earnings?

August 10, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating

August 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB Biotherapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

SABS FY2030 EPS Boosted by Brookline Capital Markets

August 7, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

August 6, 2026 | marketbeat.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

Seven Fleet Capital Management LP Takes Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

Perceptive Advisors LLC Buys 5,628,533 Shares of SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $1.53 Million Position in SAB Biotherapeutics, Inc. $SABS

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell

August 2, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) Projected to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, SABS, and IMRX Company Descriptions

Adicet Bio NASDAQ:ACET

$8.88 -0.13 (-1.44%)

As of 01:53 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ADMA Biologics NASDAQ:ADMA

$9.43 -0.05 (-0.53%)

As of 01:57 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Immuneering NASDAQ:IMRX

$5.02 -0.19 (-3.65%)

As of 01:58 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$3.84 -0.09 (-2.29%)

As of 01:57 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, SABS, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, SABS, and IMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, SABS, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, SABS, and IMRX Company Descriptions

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Immuneering NASDAQ:IMRX

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACET, ADMA, SABS, and IMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACET, ADMA, SABS, and IMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACET, ADMA, SABS, and IMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACET, ADMA, SABS, and IMRX Company Descriptions

Adicet Bio NASDAQ:ACET

ADMA Biologics NASDAQ:ADMA

Immuneering NASDAQ:IMRX

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools